- Home
- AARD vs PLRX Comparison
AARD vs PLRX Comparison
Compare AARD & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | PLRX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.7M | 81.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AARD | PLRX |
|---|---|---|
| Price | $5.68 | $1.29 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | ★ $15.29 | $2.67 |
| AVG Volume (30 Days) | 215.1K | ★ 421.0K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $1.09 |
| 52 Week High | $17.94 | $1.95 |
Technical Indicators
Market Signals| Indicator | AARD | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.15 | 49.09 |
| Support Level | $4.74 | $1.12 |
| Resistance Level | $6.19 | $1.38 |
| Average True Range (ATR) | 0.36 | 0.08 |
| MACD | 0.42 | -0.00 |
| Stochastic Oscillator | 96.05 | 59.09 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.